Intarcia's Once-Yearly Diabetes Drug Bests Januvia
This article was originally published in Scrip
Will positive Phase III results for ITCA 650 versus Merck & Co.'s Januvia (sitagliptin) allow Intarcia Therapeutics to convince payers that its once- or twice-yearly diabetes medicine should be a first choice therapy for patients who fail to control their glucose with metformin?
You may also be interested in...
Intarcia announced $215m in new equity financing and revised its NDA submission timeline for the second time since it reported positive Phase III results for ITCA 650 versus Januvia in mid-2015.
Gene editing is all the rage in biotechnology these days, but Caribou Biosciences Inc. has taken a different path than its CRISPR peers by diversifying beyond therapeutics to agriculture, industrial and applied research. The company also has taken a different financing path – recently closing a $30m Series B venture capital round instead of pursuing an initial public offering.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.